Form 483

Rx Compounding Inc. Form 483, 2013-03-21

FDA issued a Form 483 to Rx Compounding Inc. on 2013-03-21 with 6 public-safe observations.

483· Form 483 issuedHuman Drugs6 observations

Rx Compounding Inc. · Indianapolis, United States · Issued March 21, 2013

Overview

  • 6 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

21 Mar 2013
21 CFR 211.42(c)(10)(iv)

Environmental Monitoring System

Cited by Marie A Fadden, Larry K Austin

21 Mar 2013
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Marie A Fadden, Larry K Austin

21 Mar 2013
21 CFR 211.113(b)

Procedures for sterile drug products

Cited by Marie A Fadden, Larry K Austin

21 Mar 2013
21 CFR 211.165(a)

Testing and release for distribution

Cited by Marie A Fadden, Larry K Austin

21 Mar 2013
21 CFR 211.165(b)

Microbiological testing

Cited by Marie A Fadden, Larry K Austin

Inspected site

RCRx Compounding Inc.Indianapolis, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.165(a)Cited across public-safe Form 483 observations1x
21 CFR 211.165(b)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(iv)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 6 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere